Your knockout takes the whole protein. Your small molecule needs a pocket it can't find. There's a third option. The tool just wasn't available yet.
As a scientist, you might not have been told that engineered protein binders are an option for your research. This is not a gap in your training. It is a gap in how the field communicates.
A protein binder is a precision molecular tool designed to engage one surface on one protein. You can finally disrupt the interaction you have been circling for years without needing a pocket, without a KO, and without off target noise. You now have access to technology that has been out of reach.
You know the pathway, the interaction, and the phenotype you are after. You do not need to know how to design binders. You only need to bring the question and receive the engineered answer.
Submit your target brief and describe the interaction you want to disrupt. Your project moves seamlessly through generative design, DEL synthesis, affinity selection, and cellular validation.
Receive cell validated binders as research ready reagents. You will not have to learn a new workflow or buy new equipment. You get the precise perturbation your experiment has been waiting for.
One surface. Target the interface directly with no pocket geometry required.
One domain. Silence the function you care about while the rest of your protein stays intact.
Cell validated. Confirmed by a cell-based assay before it reaches your bench.
A highly reproducible milestone framework tailored to your program's specific binding parameters. Progress is measured by data generation, not arbitrary timelines.
Partners securely upload structural files via our air-gapped intake portal. The ProxAI engine maps the exact geometric coordinates and uncovers hidden interaction hotspots on flat surfaces.
Our deep learning models generate over 100,000 completely de novo candidate sequences custom-tailored to bind exclusively with the identified hotspot geometry.
The library shifts to physical cell systems. Using automated multi-parameter FACS tracking, we screen millions of cellular variants in real-time, pulling out elite binders, regardless if your target is intracellular.
Top binder assets undergo meticulous characterization, and cross-reactive safety assays to ensure absolute specificity. Access data through our secured portal.
Not catalog-first. Target-first.
Four binder chassis, chosen strictly on the merits of your binding interface.
Fab / scFv designs with established manufacturing and regulatory precedent.
Single-domain VHH framework with camelid-derived loop flexibility.
De novo scaffolds offering high stability and precise interface targeting.
Constrained macrocycles with cell permeability and oral bioavailability potential.
By exploiting native cellular regulation mechanisms, you can engineer high-precision binders to execute completely distinct therapeutic modalities.
Direct, high-affinity competitive disruption of targeted protein-protein interaction interfaces. Our binders act as physical shields, shutting down down-stream oncogenic signaling across traditionally undruggable flat surfaces.
Bifunctional chimera systems that hijack native cell biology. By mechanically cross-linking your target straight to intracellular degradation machineries, we achieve complete catalytic elimination of the target protein.
Real-time performance metrics from the ProxAI Engine.
From sequence design to Validated Lead.
Comparing AI-Fold to Ground Truth
Engineered by pioneers at the intersection of generative deep learning and cell biology.
Backed by industry-leading clinical translational expertise.
Architect of the ProxAI generative engine. Computational cell biologist specializing in Protein-Protein Interactions and proteomics data analysis.
Pioneer in protein degradation and immunology. Leads the high-throughput experimental validation loop for all in-house modalities.
Guides late-stage lead optimization and IND-enabling strategies. Provides business guidance.
Full professor at the University of Montreal. Leader in immunology and Parkinson's disease research.
President and Scientific Director at the IRCM. Full professor at the University of Montreal. Leader in biomolecules and oncology research.
Guides late-stage lead optimization and IND-enabling strategies for induced proximity targets.
Seasoned leader with broad experience across strategy, marketing, talent management, and operational roles within the digital health, biotech, and pharmaceutical industries.
Seasoned biotech entrepreneur with 30+ years founding, scaling, and commercializing innovative life science technologies. Leader in industrialization and market launches.
Connect with our business development and scientific advisory teams.
Submit your details below to schedule an exploratory briefing and initiate mutual NDAs.
Embedded within the prestigious IRCM, our physical laboratory bridges the critical gap between in silico generation and in vitro reality.
Rapid, large-scale screening of computationally engineered binders. Executing proprietary validation workflows within native cellular contexts.
Direct integration with top-tier microscopy, genomics, proteomics, immunology, and oncology resources, enabling accelerated development pipelines.
